Table 3 Clinical trials for therapies directly targeting CAFs

FAP

Sibrotuzumab

Mono

CRC

II

NCT02198274

Futility

[273]

Talabostat

Mono

CRC

II

–

SD (21%)

[274]

Talabostat

Chemo

Melanoma

II

NCT00083252

ORR (12.5%)

[275]

Talabostat

ICI

CRPC

Ib/II

NCT03910660

–

[276]

Talabostat

ICI

PDAC

II

NCT05558982

–

[277]

¹⁷⁷Lu-FAP-2286

Mono

Solid

I/II

NCT04939610

Safe

[284]

¹⁷⁷Lu-EB-FAPI

Mono

Solid

I

NCT05400967

–

–

¹⁷⁷Lu-DOTA-FAPI

Mono

Solid

I

NCT04849247

Safe

[288]

¹⁷⁷Lu-DOTA-EB-FAPI

Mono

Thyroid

I

NCT05410821

DCR (83%)

ORR (25%)

[289]

¹⁷⁷Lu-DOTA-EB-FAPI

Mono

Solid

I

NCT05963386

–

–

¹⁷⁷Lu-PNT6555

Mono

Solid

I

NCT05432193

–

–

¹⁷⁷Lu-LCN1004

Mono

Solid

I

NCT05723640

–

–

CART-FAP

Mono

MPM

I

NCT01722149

Safe

[282]

RO6874281

Mono

Solid

I

NCT02627274

Safe

[278]

RO6874813

Mono

Solid

I

NCT02558140

Safe

[280]

RO7122290

ICI

Solid

Ib/II

NCT04826003

ORR (18.4%)

[281]

RO7300490

Mono, ICI

Solid

I

NCT04857138

–

–

PDGFR

Imatinib

ICI

Solid

I

NCT01738139

Safe

[293]

Imatinib

ICI

Melanoma

Ib/II

NCT04546074

–

[294]

Regorafenib

ICI

CRC

–

NCT04771715

SD (45%)

PR (5%)

[321]

Sunitinib

ICI

Sarcoma

1b/II

NCT03277924

PFS (48%)

[322]

Olaratumab

Chemo

Sarcoma

III

NCT02451943

Futility

[296]

Olaratumab

ICI

Sarcoma

NCT03126591

Safe

[297]

HH

Sonidegib

Mono

BCC

II

NCT01327053

ORR (48.1%)

[304]

Sonidegib

Chemo

TNBC

I

NCT02027376

ORR (30%)

[305]

Sonidegib

ICI

NSCLC

I

NCT04007744

Safe

[306]

Vismodegib

Mono

BCC

II

NCT02667574

ORR (71%)

[307]

Vismodegib

Mono

GC

II

NCT03052478

DCR (5.3%)

[308]

Vismodegib

Chemo

Pancreatic

II

NCT01088815

Futility

[309]

FSP-1

Niclosamide

Mono

CRC

II

NCT02519582

Safe

[312]

LRRC15

ABBV-085

Mono

Solid

I

NCT02565758

ORR (20%)

[317]

IL-1R

Anakinra

Chemo, targeted

CRC

II

NCT02090101

SD (68.8%)

ORR (15.6%)

[319]

Anakinra

CAR-T

MM

1b/II

NCT03430011

Safe

[320]